Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV
Diabetes Care · 01.10.2025 · 48 (10) · 1761-1765
DOI: 10.2337/dc25-0236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 19.09.2025. Verfasst von Andrew W Hahn und 25 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington, Seattle, WA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, HIV Infections, Hypoglycemic Agents, Healthcare Disparities. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, NIDA NIH HHS.
Abstract (Originalsprache)
OBJECTIVE To evaluate semaglutide use among people with HIV (PWH) with medical indications by race and ethnicity. RESEARCH DESIGN AND METHODS We identified PWH in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort at nine sites eligible for semaglutide therapy between 2019 and 2023. Semaglutide eligibility was based on BMI ≥30 or HbA1c ≥6.5. We evaluated differences in semaglutide receipt among eligible PWH by race and ethnicity using relative risk regression adjusted for demographic characteristics. RESULTS Among 11,617 eligible PWH, 774 (6.7%) received semaglutide (92% eligible by BMI ≥30, 62% by HbA1c ≥6.5, and 54% by both criteria). Eligible Black PWH were 20% less likely to receive semaglutide versus White PWH (prevalence ratio [PR] 0.80, 95% CI 0.67–0.95). The lower rate of semaglutide for Black (PR 0.66, 95% CI 0.53–0.83) and Hispanic PWH (PR 0.70, 95% CI 0.53–0.93) was more pronounced among those with higher HbA1c (≥8.0). CONCLUSIONS We describe inequitable semaglutide use among PWH, with lower initiation rates in eligible Black PWH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Washington, Seattle, WA.
- University of Manitoba, Winnipeg, Manitoba, CA.
- The Fenway Institute, Harvard Medical School, Boston, MA.
- University of North Carolina, Chapel Hill, NC.
- University of California San Francisco, San Francisco, CA.
- University of California San Diego, La Jolla, CA.
ORCID-Profile: Andrew W Hahn
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
- NIDA NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Heart, Lung, and Blood Institute
- National Institute on Drug Abuse
Zitieren
APA
Hahn, A. W., Ruderman, S. A., Nance, R. M., Whitney, B. M., Eltonsy, S., Haidar, L., Drumright, L. N., Ma, J., Mayer, K. H., Napravnik, S., Eron, J. J., Christopoulos, K. A., Bamford, L., Cachay, E. R., Yendewa, G., Pettit, A., Saag, M. S., Heath, S. L., Moore, R. D., …, & Fredericksen, R. J. (2025). Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV. Diabetes Care, 48(10), 1761-1765. https://doi.org/10.2337/dc25-0236
Vancouver
Hahn AW, Ruderman SA, Nance RM, Whitney BM, Eltonsy S, Haidar L, et al. Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV. Diabetes Care. 2025;48(10):1761-1765. doi:10.2337/dc25-0236
BibTeX
@article{Hahn2025,
author = {Hahn, Andrew W and Ruderman, S A and Nance, R M and Whitney, B M and Eltonsy, S and Haidar, L and Drumright, L N and Ma, J and Mayer, K H and Napravnik, S and Eron, J J and Christopoulos, K A and Bamford, L and Cachay, E R and Yendewa, G and Pettit, A and Saag, M S and Heath, S L and Moore, R D and Keruly, J C and Batey, D S and Chander, G and Kitahata, M M and Delaney, J A C and Crane, H M and Fredericksen, R J},
title = {Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV},
journal = {Diabetes Care},
year = {2025},
volume = {48},
number = {10},
pages = {1761--1765},
doi = {10.2337/dc25-0236}
}
EUVIMED